

## Lynparza<sup>®</sup> (olaparib) – New indication

- On January 12, 2018, the [FDA announced](#) the approval of [AstraZeneca's Lynparza \(olaparib\)](#) tablets, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
  - Patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment.
  - Select patients for therapy based on an FDA-approved companion diagnostic, [BRCAAnalysis CDx<sup>®</sup>](#), for Lynparza.
- Lynparza is also approved for the treatment of ovarian cancer as follows:
  - For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
  - For the treatment of adult patients with deleterious or suspected deleterious gBRCAm advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
- Lynparza is also available as a 50 mg [capsule](#) approved for in patients with advanced gBRCAm ovarian cancer after three or more lines of chemotherapy.
- According to the [National Cancer Institute](#), there were 252,710 new cases of breast cancer and 40,610 deaths from breast cancer in 2017 in the U.S.
  - Approximately 20 – 25% of patients with hereditary breast cancers and 5 – 10% of patients with any type of breast cancer have a BRCA mutation.
- Lynparza is the first poly ADP-ribose polymerase inhibitor approved to treat breast cancer. Lynparza is the first drug approved to treat certain patients with metastatic breast cancer who have a gBRCAm.
- The new indication of Lynparza was approved based on a randomized study of 302 patients with HER2-negative metastatic breast cancer with gBRCAm. Patients received Lynparza or chemotherapy. The major efficacy measure was progression free survival (PFS).
  - The median PFS for patients taking Lynparza was 7 months vs. 4.2 months for patients taking chemotherapy (HR = 0.58 [95% CI: 0.43, 0.80]; p = 0.0009).
  - The objective response rate was 52% (95% CI: 44, 60) for the Lynparza arm vs. 23% (95% CI: 13, 35) for the chemotherapy arm.
- The recommended dosage of Lynparza for all indications is 300 mg (two 150 mg tablets) taken orally twice daily, with or without food, for a total daily dose of 600 mg.

- Lynparza tablets (100 mg and 150 mg) should not be substituted with Lynparza capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.